Carrie A Cunningham

发表

Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others.

S. Pinder, H. Earl, D. Rea, 2016, Journal of the National Cancer Institute.

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

E. Winer, O. Bogler, I. Hedenfalk, 2021, NPJ breast cancer.

In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer

J. Bartlett, D. Cameron, E. Mallon, 2012, Breast Cancer Research and Treatment.

Proximity ligation assays for isoform‐specific Akt activation in breast cancer identify activated Akt1 as a driver of progression

G. Kerr, J. Bartlett, D. Cameron, 2012, The Journal of pathology.

Evaluation of multiple transcriptomic gene risk signatures in male breast cancer

O. Bogler, I. Hedenfalk, P. Porter, 2021, npj Breast Cancer.

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance

J. Reis-Filho, J. Bartlett, A. Mackay, 2014, BMC Cancer.

G. Kerr, J. Bartlett, D. Cameron, 2013, The Journal of pathology.

Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial

J. Donovan, S. Pinder, A. Makris, 2015 .

Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer

J. Donovan, S. Pinder, H. Earl, 2015 .